Form 4: Eli Lilly Director Karen Walker Acquires Shares in Open Market Transaction

Director Karen Walker acquired 302.53 shares of Eli Lilly common stock at a price of $727.2 per share on November 18, 2024.

Summary

• Karen Walker, a director at Eli Lilly & Co, acquired 302.53 shares of common stock on November 18, 2024.
• The purchase price was $727.2 per share.
• Following the transaction, Ms. Walker's total holdings of Eli Lilly common stock increased to 6,248.823 shares.

Sentiment

Score: 6

Explanation: The document reflects a routine insider transaction, which is neither particularly positive nor negative. The purchase by a director could be seen as a slightly positive signal, but it's not a major event.

Positives

• The purchase of shares by a director can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a routine filing related to insider trading activity. It is common for directors and officers to buy or sell shares of their company, and these transactions are reported to the SEC.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this transaction is consistent with typical insider trading activity.
• Other pharmaceutical companies such as Pfizer (PFE) and Johnson & Johnson (JNJ) also have similar filings when their directors or officers trade company stock.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates a director's confidence in the company.

Key Dates

Keywords

insider trading, Form 4, stock acquisition, director, Eli Lilly, LLY, Karen Walker